当前位置: X-MOL 学术JAMA Surg. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Bladder Extirpation vs PreservationThe Treatment Debate
JAMA Surgery ( IF 15.7 ) Pub Date : 2018-10-01 , DOI: 10.1001/jamasurg.2018.1674
David B. Cahn 1 , Elizabeth A. Handorf 2 , Marc C. Smaldone 1
Affiliation  

Level 1 evidence supports neoadjuvant chemotherapy followed by a radical cystectomy (RC) for treating muscle-invasive bladder cancer (MIBC).1 Given its substantial perioperative morbidity, bladder preservation therapy (BPT) is an alternative treatment option for individuals who wish to avoid or are not able to undergo RC.2 Given the absence of prospective randomized clinical trials, well-designed observational cohort studies currently offer the best comparative effectiveness evidence to evaluate these treatment options.



中文翻译:

膀胱切除术与保留疗法的争论

1级证据支持新辅助化疗,然后行根治性膀胱切除术(RC)治疗肌肉浸润性膀胱癌(MIBC)。1鉴于其围手术期的高发病率,对于希望避免或无法进行RC的个体,膀胱保留疗法(BPT)是一种替代治疗选择。2由于缺乏前瞻性随机临床试验,设计良好的观察性队列研究目前提供最佳的比较有效性证据,以评估这些治疗方案。

更新日期:2018-10-18
down
wechat
bug